| Literature DB >> 31806027 |
Ruth Aguilar1, Joseph J Campo1,2, Silvia Chicuecue2, Pau Cisteró1, Alba Català1, Leopoldina Luis2, Itziar Ubillos1, Beatriz Galatas1,2, Pedro Aide2, Caterina Guinovart1,2, Gemma Moncunill3, Carlota Dobaño4.
Abstract
BACKGROUND: Malaria epidemiological and immunological data suggest that parasite tolerance wanes in the absence of continuous exposure to the parasite, potentially enhancing pathogenesis. The expansion of control interventions and elimination campaigns raises the necessity to better understand the host factors leading to susceptibility or tolerance that are affected by rapid changes in malaria transmission intensity (MTI). Mediators of cellular immune responses are responsible for the symptoms and pathological alterations during disease and are expected to change rapidly upon malaria exposure or cessation.Entities:
Keywords: Age; Antibodies; Chemokines; Cytokines; Growth factors; Immunity; Malaria transmission intensity; Plasmodium falciparum; Tolerance
Mesh:
Substances:
Year: 2019 PMID: 31806027 PMCID: PMC6896751 DOI: 10.1186/s12936-019-3038-x
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Weighted malaria prevalences and number of febrile infections in the study area and neighbourhoods, determined by microscopy and real time quantitative polymerase chain reaction (qPCR)
| Diagnostic | 2010 | 2013 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Individuals tested | Infected | Weighted prevalence of infection (%) | Lower 95% CI | Upper 95% CI | Febrile infections | Individuals tested | Infected | Weighted prevalence of infection (%) | Lower 95% CI | Upper 95% CI | Febrile infections | ||
| Whole study areaa | Microscopy | 975 | 13 | 1.11 | 0.56 | 2.21 | 3 (23%) | 944 | 45 | 5.22 | 3.64 | 7.42 | 18 (40%) |
| qPCR | 970 | 106 | 12.59 | 10.09 | 15.6 | 15 (14%) | 808 | 162 | 23.86 | 20.18 | 27.99 | 43 (26%) | |
| Maragra | Microscopy | 224 | 3 | 0.9 | 0.22 | 3.64 | 1 (33%) | 206 | 5 | 3.9 | 1.57 | 9.35 | 4 (80%) |
| qPCR | 223 | 33 | 17.31 | 11.85 | 24.6 | 3 (9%) | 171 | 23 | 18.8 | 12.19 | 27.86 | 5 (22%) | |
| Manhiça | Microscopy | 297 | 2 | 0.23 | 0.06 | 0.91 | 1 (50%) | 362 | 12 | 3.21 | 1.51 | 6.68 | 2 (17%) |
| qPCR | 299 | 27 | 9.27 | 5.84 | 14.42 | 4 (15%) | 298 | 45 | 17.37 | 12.34 | 23.89 | 6 (13%) | |
| Malavele | Microscopy | 56 | 1 | 2.55 | 0.36 | 16.13 | 1 (100%) | 52 | 4 | 11.87 | 3.55 | 33.05 | 2 (50%) |
| qPCR | 55 | 7 | 13.75 | 5.68 | 29.67 | 2 (28%) | 48 | 10 | 19.49 | 8.35 | 39.17 | 5 (50%) | |
| Palmeira | Microscopy | 206 | 3 | 1.11 | 0.27 | 4.46 | 0 (0%) | 195 | 6 | 3.43 | 1.31 | 8.68 | 2 (33%) |
| qPCR | 205 | 15 | 8.9 | 4.84 | 15.8 | 1 (7%) | 174 | 42 | 31.19 | 22.91 | 40.87 | 12 (28%) | |
| Ilha Josina | Microscopy | 124 | 3 | 4.2 | 1.11 | 14.65 | 0 (0%) | 76 | 17 | 24.47 | 13.94 | 39.33 | 7 (41%) |
| qPCR | 120 | 21 | 23.95 | 14.73 | 36.47 | 4 (19%) | 70 | 34 | 52 | 36.98 | 66.67 | 13 (38%) | |
| Taninga | Microscopy | 68 | 1 | 0.51 | 0.07 | 3.58 | 0 (0%) | 52 | 1 | 0.5 | 0.07 | 3.56 | 1 (100%) |
| qPCR | 68 | 3 | 5.68 | 1.48 | 19.4 | 1 (33%) | 46 | 8 | 22.24 | 10.09 | 42.16 | 2 (25%) | |
a11 individuals participated in both surveys
Fig. 1Differences in IgG levels against apical membrane protein-1 (AMA-1) and merozoite surface protein-1 (MSP-142) between 2010 and 2013 in each of the age groups (a) and stratifying by P. falciparum infection detected by qPCR (b). Box plots representing the median and interquartile range of IgG levels (log10 OD) measured by ELISA. a Shows an increase of IgGs to both antigens along age groups within each cross-sectional (p trend < 0.001in all four cases). In (a) and (b) levels between years were compared by Wilcoxon rank-sum test (adjusted p-values for multiple testing by the Holm approach < 0.05 are shown)
Description of Plasmodium falciparum infected and uninfected study participants (defined by qPCR)
| Infected (by qPCR) | Uninfected (by qPCR) | |||||
|---|---|---|---|---|---|---|
| 2010 | 2013 | p-value | 2010 | 2013 | p-value | |
| N | 96 | 65 | 138 | 78 | ||
| Age [median (IQR)] | 9.79 (3.61–35.89) | 10.06 (3.31–27.64) | 0.462 | 28.4 (5.86–64.03) | 7.18 (3.28–36.38) | 0.002 |
| Age group (%) | 0.737 | 0.016 | ||||
| < 2 years | 8 (8.3) | 10 (15.4) | 15 (10.9) | 14 (17.9) | ||
| 2–5 years | 29 (30.2) | 16 (24.6) | 15 (10.9) | 15 (19.2) | ||
| 5–10 years | 12 (12.5) | 6 (9.2) | 15 (10.9) | 14 (17.9) | ||
| 10–20 years | 15 (15.6) | 12 (18.5) | 0 (0.0) | 1 (1.3) | ||
| 20–60 years | 23 (24.0) | 16 (24.6) | 45 (32.6) | 18 (23.1) | ||
| > 60 years | 9 (9.4) | 5 (7.7) | 48 (34.8) | 16 (20.5) | ||
| Male (%) | 42 (43.8) | 31 (47.7) | 0.632 | 49 (35.5) | 33 (42.3) | 0.381 |
| Anaemia (%) | 47 (49.0) | 28 (43.1) | 0.521 | 79 (57.2) | 39 (50.0) | 0.322 |
| Area (%) | 0.002 | < 0.001 | ||||
| Ilha Josina | 19 (19.8) | 19 (29.2) | 23 (16.7) | 4 (5.1) | ||
| Malavele | 7 (7.3) | 9 (13.8) | 12 (8.7) | 11 (14.1) | ||
| Manhiça | 26 (27.1) | 11 (16.9) | 45 (32.6) | 25 (32.1) | ||
| Maragra | 30 (31.2) | 6 (9.2) | 51 (37.0) | 15 (19.2) | ||
| Palmeira | 11 (11.5) | 16 (24.6) | 4 (2.9) | 17 (21.8) | ||
| Taninga | 3 (3.1) | 4 (6.2) | 3 (2.2) | 6 (7.7) | ||
| Par. dens. qPCR (parasites/µL) [median (IQR)] | 10.46 (1.61–102.94) | 7.61 (1.43–299.84) | 0.999 | NA | NA | |
| Clinical malaria (%) | 0.026 | NA | NA | |||
| No | 93 (96.9) | 55 (84.6) | ||||
| Yes | 3 (3.1) | 8 (12.3) | ||||
| NA | 0 (0.0) | 2 (3.1) | ||||
Continuous variables were analysed using the non-parametric Wilcoxon rank-sum test. Comparisons between groups for categorical variables were done using Fisher’s exact test. Parasite densities were log10 transformed
Fig. 2Differences in analyte concentrations between 2010 and 2013 stratified by infection. Radar charts representing the medians of each analyte concentration (log10 pg/mL) in 2010 and 2013 and stratifying in infected and uninfected subjects. Levels into each group have been compared between years by Wilcoxon rank-sum test and p-values were adjusted for multiple testing by the Benjamini–Hochberg approach. Statistically significant differences between years are highlighted with an asterisk
Fig. 3Differences in analytes concentrations between P. falciparum-infected and uninfected subjects stratified by year. Radar charts representing the medians of each analyte concentration (log10 pg/mL) in infected and uninfected subjects and stratifying by year. Levels between infected and uninfected subjects into each year have been compared by Wilcoxon rank-sum test and p-values were adjusted for multiple testing by the Benjamini–Hochberg approach. Statistically significant differences between infected and uninfected subjects are highlighted with an asterisk
Univariable and multivariable linear regression models to assess the effect of IgGs to AMA-1 and MSP-1 on the cellular immune mediator concentrations and interaction with year
| Analyte | IgG to AMA-1 | IgG to MSP-1 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable & interaction with year | Univariable | Multivariable & interaction with year | |||||||
| Coefficient (CI) | p-value | Coefficient (CI) | p-value | p-value Int | Coefficient (CI) | p-value | Coefficient (CI) | p-value | p-value Int | |
| FGF | − 0.024 (− 0.048, 0) | − 0.068 (− 0.261, 0.125) | 0.486 | 0.636 | − 0.019 (− 0.036, − 0.002) | − 0.016 (− 0.162, 0.13) | 0.829 | 0.996 | ||
| IL-1β | − 0.026 (− 0.054, 0.002) | 0.07 | − 0.046 (− 0.235, 0.144) | 0.636 | 0.658 | − 0.02 (− 0.037, − 0.003) | 0.004 (− 0.124, 0.132) | 0.956 | 0.954 | |
| G-CSF | − 0.002 (− 0.009, 0.004) | 0.419 | − 0.046 (− 0.091, 0) | 0.058 | − 0.002 (− 0.006, 0.002) | 0.359 | − 0.026 (− 0.062, 0.009) | 0.146 | 0.155 | |
| IL-10 | − 0.009 (− 0.035, 0.017) | 0.511 | − 0.098 (− 0.29, 0.094) | 0.315 | 0.331 | 0.001 (− 0.017, 0.02) | 0.886 | − 0.122 (− 0.272, 0.029) | 0.112 | 0.086 |
| IL-13 | − 0.017 (− 0.02, − 0.007) | − 0.029 (− 0.108, 0.05) | 0.473 | 0.75 | − 0.012 (− 0.019, − 0.004) | 0.002 (− 0.06, 0.063) | 0.954 | 0.707 | ||
| IL-6 | − 0.024 (− 0.071, 0.024) | 0.335 | 0.014 (− 0.235, 0.262) | 0.914 | 0.984 | − 0.033 (− 0.067, 0.001) | 0.055 | − 0.015 (− 0.22, 0.19) | 0.888 | 0.837 |
| IL-12 | − 0.007 (− 0.012, − 0.002) | − 0.045 (− 0.083, − 0.008) | − 0.003 (− 0.007, 0) | 0.06 | − 0.01 (− 0.041, 0.021) | 0.531 | 0.639 | |||
| RANTES | 0.005 (0.001, 0.01) | 0.015 (− 0.016, 0.047) | 0.338 | 0.501 | 0.002 (− 0.001, 0.005) | 0.124 | − 0.004 (− 0.029, 0.021) | 0.769 | 0.689 | |
| Eotaxin | − 0.011 (− 0.026, 0.004) | 0.141 | − 0.103 (− 0.216, 0.01) | 0.075 | 0.106 | − 0.005 (− 0.015, 0.006) | 0.385 | − 0.037 (− 0.126, 0.052) | 0.414 | 0.458 |
| IL-17 | − 0.019 (− 0.058, 0.02) | 0.331 | 0.043 (− 0.258, 0.344) | 0.778 | 0.687 | 0.004 (− 0.024, 0.033) | 0.778 | − 0.135 (− 0.37, 0.099) | 0.256 | 0.229 |
| MIP-1α | 0.005 (− 0.014, 0.025) | 0.591 | − 0.027 (− 0.13, 0.076) | 0.611 | 0.427 | − 0.008 (− 0.021, 0.006) | 0.269 | − 0.058 (− 0.141, 0.024) | 0.166 | 0.122 |
| GM-CSF | − 0.021 (− 0.083, 0.041) | 0.5 | − 0.616 (− 1.092, − 0.141) | − 0.017 (− 0.062, 0.028) | 0.451 | − 0.336 (− 0.747, 0.075) | 0.109 | 0.113 | ||
| MIP-1β | − 0.003 (− 0.021, 0.015) | 0.76 | − 0.03 (− 0.111, 0.051) | 0.463 | 0.365 | − 0.013 (− 0.026, − 0.001) | − 0.027 (− 0.092, 0.037) | 0.409 | 0.385 | |
| MCP-1 | − 0.00 (− 0.01, 0.005) | 0.504 | − 0.061 (− 0.11, − 0.012) | − 0.007 (− 0.012, − 0.001) | − 0.062 (− 0.1, − 0.024) | |||||
| IL-15 | − 0.004 (− 0.018, 0.011) | 0.626 | 0.064 (− 0.051, 0.18) | 0.272 | 0.245 | 0.003 (− 0.007, 0.013) | 0.531 | 0.033 (− 0.058, 0.125) | 0.475 | 0.518 |
| EGF | − 0.01 (− 0.027, 0.008) | 0.27 | − 0.009 (− 0.141, 0.123) | 0.889 | 0.959 | − 0.006 (− 0.017, 0.005) | 0.289 | 0.008 (− 0.087, 0.103) | 0.871 | 0.852 |
| IL-5 | − 0.036 (− 0.081, 0.009) | 0.121 | − 0.11 (− 0.46, 0.241) | 0.539 | 0.685 | − 0.008 (− 0.041, 0.024) | 0.613 | − 0.285 (− 0.557, − 0.013) | ||
| HGF | − 0.005 (− 0.013, 0.002) | 0.16 | − 0.045 (− 0.099, 0.009) | 0.101 | 0.129 | − 0.001 (− 0.006, 0.004) | 0.632 | − 0.025 (− 0.067, 0.017) | 0.237 | 0.212 |
| VEGF | − 0.027 (− 0.049, − 0.005) | − 0.022 (− 0.037, − 0.006) | 0.096 (− 0.011, 0.203) | 0.078 | 0.055 | |||||
| IFN-γ | 0.002 (− 0.009, 0.013) | 0.747 | − 0.014 (− 0.098, 0.069) | 0.735 | 0.7 | 0.004 (− 0.004, 0.012) | 0.31 | − 0.033 (− 0.1, 0.034) | 0.33 | 0.272 |
| IFN-α | − 0.005 (− 0.012, 0.002) | 0.194 | − 0.09 (− 0.139, − 0.04) | − 0.005 (− 0.009, 0) | 0.067 | − 0.068 (− 0.106, − 0.03) | ||||
| IL-1RA | − 0.01 (− 0.018, − 0.003) | 0.025 (− 0.018, 0.068) | 0.261 | 0.145 | − 0.008 (− 0.013, − 0.002) | 0.034 (− 0.001, 0.07) | 0.055 | |||
| TNF | 0.001 (− 0.029, 0.03) | 0.953 | − 0.056 (− 0.264, 0.151) | 0.592 | 0.527 | − 0.013 (− 0.034, 0.009) | 0.242 | − 0.089 (− 0.255, 0.077) | 0.292 | 0.287 |
| IL-2 | 0.006 (− 0.03, 0.042) | 0.736 | − 0.006 (− 0.29, 0.279) | 0.968 | 0.936 | 0.018 (− 0.008, 0.043) | 0.178 | 0.005 (− 0.221, 0.23) | 0.969 | 0.907 |
| IL-7 | − 0.009 (− 0.024, 0.006) | 0.249 | − 0.027 (− 0.155, 0.102) | 0.68 | 0.781 | − 0.002 (− 0.014, 0.009) | 0.678 | 0.082 (− 0.023, 0.186) | 0.126 | 0.114 |
| IP-10 | − 0.037 (− 0.054, − 0.021) | − 0.087 (− 0.205, 0.032) | 0.152 | 0.377 | − 0.02 (− 0.031, − 0.008) | − 0.07 (− 0.163, 0.024) | 0.146 | 0.248 | ||
| IL-2R | − 0.016 (− 0.024, − 0.009) | − 0.019 − 0.079, 0.04) | 0.52 | 0.909 | − 0.008 (− 0.013, − 0.002) | 0.008 (− 0.04, 0.055) | 0.751 | 0.53 | ||
| MIG | − 0.01 (− 0.021, 0.001) | 0.079 | − 0.086 (− 0.171, − 0.002) | 0.072 | − 0.003 (− 0.011, 0.005) | 0.49 | − 0.038 (− 0.106, 0.03) | 0.275 | 0.293 | |
| IL-4 | − 0.014 (− 0.031, 0.002) | 0.085 | − 0.118 (− 0.239, 0.003) | 0.056 | 0.081 | − 0.007 (− 0.019, 0.004) | 0.201 | − 0.08 (− 0.173, 0.013) | 0.092 | 0.104 |
| IL-8 | 0.006 (− 0.02, 0.031) | 0.657 | 0.052 (− 0.073, 0.177) | 0.413 | 0.595 | − 0.016 (− 0.034, 0.003) | 0.091 | − 0.019 (− 0.118, 0.081) | 0.712 | 0.644 |
p-values < 0.05 are in italic
* p-values < 0.05 after adjusted for multiple comparisons by the Benjamini–Hochberg approach
Fig. 4Differences in concentrations of cellular immune mediators between age groups in P. falciparum-infected subjects from both years combined. Box plots representing the median and interquartile range of each analyte concentration (log10 pg/mL) in infected subjects stratified by age group. Levels between age groups have been compared by Kruskal–Wallis test. P-values were adjusted for multiple testing using the Benjamini–Hochberg approach
Fig. 5Differences in concentrations of cellular immune mediators between age groups in uninfected subjects from both years combined. Box plots representing the median and interquartile range of each analyte concentration (log10 pg/mL) in uninfected subjects stratified by age group. Levels between age groups have been compared by Kruskal–Wallis test. P-values were adjusted for multiple testing using the Benjamini–Hochberg approach
Fig. 6Differences in concentrations of cellular immune mediators between areas in uninfected subjects. Box plots representing the median and interquartile range of each analyte concentration (log10 pg/mL) in uninfected subjects stratified by neighbourhood. Levels between areas have been compared by Kruskal–Wallis test. p-values were adjusted for multiple testing using the Benjamini–Hochberg approach
Effect of parasite density (qPCR) on cellular immune mediators concentrations and interaction with year
| Analyte | Parasite density by qPCR | ||||
|---|---|---|---|---|---|
| Coefficient (CI) | p-value | p-value BH | p-value interaction | p-value interaction BH | |
| IL-1β | − 0.076 (− 0.186, 0.034) | 0.176 | 0.377 | 0.296 | 0.902 |
| IL-1RA | 0.002 (− 0.053, 0.057) | 0.945 | 0.945 | 0.143 | 0.860 |
| TNF | − 0.072 (− 0.149, 0.006) | 0.069 | 0.207 | 0.764 | 0.916 |
| IL-6 | 0.017 (− 0.122, 0.157) | 0.805 | 0.894 | 0.274 | 0.902 |
| IFN-α | − 0.015 (− 0.041, 0.011) | 0.252 | 0.472 | 0.883 | 0.916 |
| IFN-γ | − 0.025 (− 0.049, − 0.001) | 0.151 | 0.470 | 0.916 | |
| IL-12 | 0.03 (0.007, 0.053) | 0.076 | 0.894 | 0.916 | |
| IL-17 | − 0.046 (− 0.1, 0.008) | 0.097 | 0.266 | 0.409 | 0.916 |
| IL-10 | 0.157 (0.098, 0.216) | < | < | < | |
| IL-13 | − 0.057 (− 0.095, − 0.018) | 0.772 | 0.916 | ||
| IL-4 | − 0.029 (− 0.074, 0.016) | 0.207 | 0.414 | 0.912 | 0.916 |
| IL-5 | − 0.07 (− 0.126, − 0.014) | 0.090 | 0.515 | 0.916 | |
| IL-2 | − 0.022 (− 0.066, 0.023) | 0.338 | 0.590 | 0.753 | 0.916 |
| IL-2R | 0.053 (0.021, 0.085) | 0.898 | 0.916 | ||
| IL-15 | − 0.016 (− 0.063, 0.031) | 0.506 | 0.732 | 0.819 | 0.916 |
| IL-7 | − 0.193 (− 0.354, − 0.032) | 0.094 | 0.785 | 0.916 | |
| Eotaxin | − 0.04 (− 0.079, − 0.002) | 0.148 | 0.179 | 0.896 | |
| IL-8 | − 0.053 (− 0.18, 0.075) | 0.414 | 0.653 | 0.301 | 0.902 |
| IP-10 | 0.024 (− 0.027, 0.074) | 0.354 | 0.590 | 0.799 | 0.916 |
| MCP1 | 0.041 (0.002, 0.081) | 0.148 | 0.443 | 0.916 | |
| MIG | 0.035 (− 0.011, 0.081) | 0.134 | 0.334 | 0.276 | 0.902 |
| MIP-1α | − 0.027 (− 0.128, 0.074) | 0.594 | 0.742 | 0.500 | 0.916 |
| MIP-1β | − 0.004 (− 0.107, 0.098) | 0.933 | 0.945 | 0.093 | 0.697 |
| RANTES | − 0.01 (− 0.044, 0.024) | 0.561 | 0.732 | 0.896 | 0.916 |
| EGF | − 0.015 (− 0.089, 0.059) | 0.683 | 0.820 | 0.916 | 0.916 |
| FGF | − 0.007 (− 0.125, 0.112) | 0.911 | 0.945 | 0.734 | 0.916 |
| G-CSF | − 0.009 (− 0.035, 0.018) | 0.522 | 0.732 | 0.366 | 0.916 |
| GM-CSF | − 0.05 (− 0.117, 0.018) | 0.147 | 0.339 | 0.424 | |
| HGF | 0.007 (− 0.035, 0.049) | 0.733 | 0.846 | 0.712 | 0.916 |
| VEGF | 0.023 (− 0.055, 0.101) | 0.560 | 0.732 | 0.076 | 0.697 |
The effect of parasite density on analytes concentrations was assessed through multivariable linear regressions for each analyte, with analyte concentration as outcome (pg/mL) and parasitaemia as the predictor variable. Interaction tests were performed to determine if there was an interaction of parasite density with year on the analyte levels. BH: p-values adjusted for multiple testing by Benjamini–Hochberg
P-values < 0.05 are in italic
CI confidence intervals
Effect of 2013 compared to 2010 on analyte concentrations in infected and uninfected individuals
| Analytes | Coefficient (CI) | p-value | p-value BH | Coefficient (CI) adjusted | p-value adjusted* | p-value BH adjusted* |
|---|---|---|---|---|---|---|
| Infected | ||||||
| IL-1β | − 1.248 (− 1.463, − 1.034) | < | < | − 1.311 (− 1.543, − 1.079) | < | < |
| IL-1RA | − 0.638 (− 0.743, − 0.534) | < | − 0.67 (− 0.781, − 0.559) | |||
| TNF | − 0.666 (− 0.842, − 0.49) | − 0.678 (− 0.867, − 0.489) | ||||
| IL-6 | − 1.945 (− 2.144, − 1.746) | − 2.023 (− 2.239, − 1.807) | ||||
| IFN-α | − 0.025 (− 0.093, 0.043) | 0.470 | 0.486 | − 0.026 (− 0.097, 0.046) | 0.481 | 0.505 |
| IFN-γ | − 0.036 (− 0.099, 0.028) | 0.268 | 0.321 | − 0.039 (− 0.103, 0.026) | 0.235 | 0.293 |
| IL-12 | − 0.035 (− 0.096, 0.027) | 0.265 | 0.321 | − 0.029 (− 0.092, 0.033) | 0.358 | 0.410 |
| IL-17 | − 0.147 (− 0.288, − 0.006) | 0.057 | − 0.149 (− 0.295, − 0.002) | 0.064 | ||
| IL-10 | − 0.227 (− 0.391, − 0.063) | − 0.235 (− 0.407, − 0.063) | ||||
| IL-13 | − 0.119 (− 0.22, − 0.017) | − 0.149 (− 0.252, − 0.046) | ||||
| IL-4 | − 0.076 (− 0.193, 0.042) | 0.205 | 0.267 | − 0.073 (− 0.196, 0.051) | 0.245 | 0.295 |
| IL-5 | − 0.018 (− 0.167, 0.132) | 0.815 | 0.815 | − 0.033 (− 0.187, 0.121) | 0.673 | 0.673 |
| IL-2 | − 0.064 (− 0.181, 0.052) | 0.278 | 0.321 | − 0.056 (− 0.177, 0.066) | 0.369 | 0.410 |
| IL-2R | − 0.126 (− 0.21, − 0.042) | − 0.123 (− 0.202, − 0.043) | ||||
| IL-15 | − 0.182 (− 0.302, − 0.063) | − 0.168 (− 0.294, − 0.043) | ||||
| IL-7 | − 0.819 (− 1.228, − 0.411) | − 0.858 (− 1.279, − 0.436) | ||||
| Eotaxin | − 0.043 (− 0.145, 0.058) | 0.401 | 0.430 | − 0.066 (− 0.173, 0.04) | 0.221 | 0.288 |
| IL-8 | − 1.769 (− 1.956, − 1.582) | − 1.868 (− 2.067, − 1.669) | ||||
| IP-10 | − 0.242 (− 0.369, − 0.116) | − 0.227 (− 0.36, − 0.094) | ||||
| MCP1 | − 0.29 (− 0.384, − 0.196) | − 0.284 (− 0.385, − 0.182) | ||||
| MIG | − 0.061 (− 0.181, 0.059) | 0.313 | 0.348 | − 0.044 (− 0.169, 0.081) | 0.488 | 0.505 |
| MIP-1α | − 1.14 (− 1.335, − 0.946) | − 1.2 (− 1.41, − 0.991) | ||||
| MIP-1β | − 1.413 (− 1.565, − 1.26) | − 1.454 (− 1.622, − 1.287) | ||||
| RANTES | 0.143 (0.056, 0.23) | 0.109 (0.018, 0.201) | ||||
| EGF | − 0.61 (− 0.778, − 0.442) | − 0.684 (− 0.858, − 0.511) | ||||
| FGF | − 0.754 (− 1.04, − 0.467) | − 0.935 (− 1.222, − 0.648) | ||||
| G-CSF | − 0.1 (− 0.169, − 0.032) | − 0.096 (− 0.167, − 0.026) | ||||
| GM-CSF | − 0.291 (− 0.462, − 0.12) | − 0.345 (− 0.524, − 0.167) | ||||
| HGF | − 0.16 (− 0.268, − 0.053) | − 0.154 (− 0.261, − 0.046) | ||||
| VEGF | − 0.913 (− 1.057, − 0.769) | − 0.967 (− 1.118, − 0.816) | ||||
| Uninfected | ||||||
| IL-1β | − 2.586 (− 2.949, − 2.223) | < | < | − 2.551 (− 2.961, − 2.14) | < | < |
| IL-1RA | − 0.501 (− 0.597, − 0.406) | < | < | − 0.523 (− 0.628, − 0.418) | < | < |
| TNF | − 0.684 (− 0.877, − 0.49) | < | < | − 0.699 (− 0.917, − 0.48) | < | < |
| IL-6 | − 2.876 (− 3.129, − 2.623) | < | < | − 2.878 (− 3.162, − 2.595) | < | < |
| IFN-α | − 0.291 (− 0.344, − 0.239) | < | < | − 0.288 (− 0.347, − 0.23) | < | < |
| IFN-γ | 0.002 (− 0.076, 0.08) | 0.960 | 0.960 | − 0.001 (− 0.087, 0.085) | 0.975 | 0.975 |
| IL-12 | − 0.129 (− 0.19, − 0.068) | < | < | − 0.158 (− 0.217, − 0.098) | < | < |
| IL-17 | 0.072 (− 0.085, 0.228) | 0.369 | 0.410 | 0.054 (− 0.121, 0.229) | 0.544 | 0.628 |
| IL-10 | − 0.391 (− 0.53, − 0.251) | < | < | − 0.376 (− 0.532, − 0.221) | < | < |
| IL-13 | − 0.264 (− 0.404, − 0.123) | < | < | − 0.272 (− 0.432, − 0.112) | ||
| IL-4 | − 0.245 (− 0.342, − 0.148) | < | < | − 0.233 (− 0.34, − 0.125) | < | < |
| IL-5 | 0.046 (− 0.086, 0.178) | 0.493 | 0.510 | 0.066 (− 0.083, 0.215) | 0.386 | 0.464 |
| IL-2 | 0.076 (− 0.13, 0.282) | 0.467 | 0.501 | 0.012 (− 0.201, 0.224) | 0.914 | 0.946 |
| IL-2R | − 0.12 (− 0.247, 0.007) | 0.064 | 0.087 | − 0.195 (− 0.319, − 0.072) | ||
| IL-15 | − 0.22 (− 0.546, 0.106) | 0.184 | 0.224 | − 0.356 (− 0.711, − 0.001) | 0.062 | |
| IL-7 | − 0.868 (− 1.188, − 0.549) | < | < | − 0.917 (− 1.264, − 0.579) | < | < |
| Eotaxin | − 0.081 (− 0.177, 0.015) | 0.099 | 0.129 | 0.011 (− 0.089, 0.112) | 0.824 | 0.883 |
| IL-8 | − 2.096 (− 2.287, − 1.904) | < | < | − 2.127 (− 2.339, − 1.916) | < | < |
| IP-10 | − 0.343 (− 0.436, − 0.25) | < | < | − 0.337 (− 0.441, − 0.233) | < | < |
| MCP1 | − 0.527 (− 0.615, − 0.44) | < | < | − 0.515 (− 0.614, − 0.416) | < | < |
| MIG | − 0.076 (− 0.215, 0.062) | 0.279 | 0.322 | − 0.033 (− 0.186, 0.12) | 0.673 | 0.748 |
| MIP-1α | − 1.267 (− 1.442, − 1.093) | < | < | − 1.299 (− 1.497, − 1.101) | < | < |
| MIP-1β | − 1.484 (− 1.629, − 1.349 | < | < | − 1.478 (− 1.638, − 1.319) | < | < |
| RANTES | 0.129 (0.05, 0.209) | 0.164 (0.087, 0.241) | < | < | ||
| EGF | − 1.555 (− 1.855, − 1.255) | < | < | − 1.682 (− 2.004, − 1.359) | < | < |
| FGF | − 0.201 (− 0.499, 0.098) | 0.187 | 0.224 | − 0.336 (− 0.662,− 0.011) | 0.056 | |
| G-CSF | − 0.211 (− 0.307, − 0.114) | < | < | − 0.236 (− 0.341, − 0.131) | < | < |
| GM-CSF | − 0.195 (− 0.354, − 0.036) | − 0.195 (0.374, − 0.016) | ||||
| HGF | − 0.29 (− 0.364, − 0.215) | < | < | − 0.305 (− 0.386, − 0.225) | < | < |
| VEGF | − 1.887 (− 2.159, − 1.614) | < | < | − 1.938 (− 2.235, − 1.641) | < | < |
The effect of year on analyte concentrations was assessed through univariable l and multivariable (adjusted models) separate linear regressions for each analyte, with analyte concentration (pg/mL) as outcome and year (2013 vs 2010) as the predictor variable. The analysis is presented separately for the infected and uninfected subjects. BH: P-values adjusted for multiple testing by Benjamini–Hochberg
P-values < 0.05 are in italic
CI confidence intervals
* Adjusted by age group and area